Infarmed ‘evaluating’ other Covid vaccines, as well as vaccines ‘adapted to variants’

Concluding her intervention in the ongoing meeting at Infarmed headquarters in Lisbon, Fátima Ventura has said contracts with suppliers “provide for the provision of vaccines adapted to Covid-19 variants”. Meantime the current vaccines are being evaluated ahead of green-lighting in Portugal: Novavax, Curevac, Sanofi, Sputnik V and Sinovac. Novavax and Sanofi are ‘protein based’; Curevac uses mRNA technology; Sputnik V is ‘viral vector’ and Sinovac uses an inactive virus.